Drugs / LQ036
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04993443 | Sep 2021 → Mar 2023 | asthma | Syneos Health | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07589439 | Sep 2025 → Sep 2027 expected | asthma | Shanghai Novamab Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LQ036 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07589439 ↗ |
| Route | Inhaled | “via inhalation” NCT04993443 ↗ |